They are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.Their biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability. They will particularly focus on the cross-talk between the immune system and brain disorders and how immune dysregulation affects central nervous system (CNS) function. Their drug discovery efforts will focus on neuropsychiatric disorders that although phenotypically distinct are pathogenically related. They aim to focus on mechanism-based immune treatments for the treatment of these disorders. Their secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician/medical providers to administer intravenous infusions of ketamine. Operations will initially take place across the United States and the United Kingdom through partnerships with healthcare companies, including with Zen Healthcare and The IV Doc Inc. (“The IV Doc”).